Sein Néoadjuvant
ULTIMATE
A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant
Paris, Saint-Cloud
PAUL-HENRI COTTU, ETIENNE BRAIN
Sein Néoadjuvant
ALIENOR
Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study)
Paris, Saint-Cloud
Appareil Digestif
REGIRI (PRODIGE 58)
A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas
Paris, Saint-Cloud
Appareil Digestif
DS8201-A-U207 DESTINY CRC02
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
Saint-Cloud
Appareil Digestif
IMMUNO-BIL (D48-1 PRODIGE 57)
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Saint-Cloud
Appareil Digestif
APACaP
Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Saint-Cloud
Sein Néoadjuvant
GANEA 3
Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma.
Saint-Cloud
EUGENIE GUILLOT, EUGENIE GUILLOT
Sein Néoadjuvant
FIGARO
Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse
Saint-Cloud
Appareil Digestif
PERSPECTIVE (MS202202-0002)
A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)
Saint-Cloud